The agreement is initially set for three years, with an option for extension, and both companies aim to expand this collaboration to other Nordic markets in the future.

The integration of Tetra Pharm Technologies' ZYNDIKATE^® technology into DanCann Pharma's product represents a significant enhancement of their offerings.  

ZYNDIKATE^® is an advanced drug delivery system specifically designed for lipophilic molecules like cannabinoids, ensuring optimal protection, absorption, and release into the bloodstream. This technology addresses common challenges associated with the oral administration of poorly soluble drugs, thereby improving their therapeutic effect.

"Partnering with Tetra Pharm Technologies to incorporate their ZYNDIKATE^® drug delivery technology into our portfolio aligns perfectly with our mission to provide innovative and effective cannabinoid therapies," said Jeppe Krog Rasmussen, CEO of DanCann Pharma.

"This collaboration not only broadens our product range but also enhances the quality and consistency of treatments available to patients. We are excited about the potential of this partnership to set new standards in cannabinoid-based medicine."

The contract underscores Tetra Pharm Technologies' commitment to advancing its Contract Development and Manufacturing Organization (CDMO) business by providing partners with cutting-edge technological solutions.

"We are thrilled to leverage innovative scientific solutions to tackle complex challenges, especially in enhancing patient outcomes through groundbreaking therapies." said Martin Rose, CEO of Tetra Pharm Technologies.

"Our ZYNDIKATE^® drug delivery technology enhances the bioavailability of lipophilic drugs, ensuring efficient absorption and targeted therapeutic effects. By partnering with DanCann Pharma, we aim to bring these advancements to a broader patient population in Denmark and, eventually, across the Nordic region."

The ambition for the launch is that the first cannabinoid medicine based on the ZYNDIKATE^® drug delivery technology will be available to Danish patients during H1-2026.

For further information, please contact:

DanCann Pharma:

Jeppe Krog Rasmussen, CEO

E-mail: jkr@dancann.com

Tetra Pharm Technologies:

Tue Wettergreen Paltorp, PR Manager

E-mail: tue.paltorp@tetrapharm.eu

About DanCann Pharma A/S

DanCann Pharma A/S is a Danish biopharmaceutical company focused on the discovery, development, production, and commercialization of cannabinoid-based medicines for patients with unmet medical needs. The company aims to provide qualified and standardized products manufactured according to standards applicable to conventional medicines. For more information, please visit www.dancann.com

About Tetra Pharm Technologies ApS

Tetra Pharm Technologies is a Danish biopharmaceutical company that specializes in the development of pharmaceutical drugs aimed at the central nervous system and the immune system to treat neurological diseases and mental health disorders. In addition to a strong clinical pipeline with lead candidates targeting chronic pain, Alzheimer's and obesity, Tetra Pharm Technologies offers a suite of tailored end-to-end CDMO services that leverages the company's proprietary drug delivery technology, ZYNDIKATE^®. For more information, please visit www.tetrapharm.eu

Forward-looking-statement:

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.